Use of platelet rich plasma composition in the treatment of cardiac conduction abnormalities
Methods and kits for treating a cardiac arrhythmia using a platelet rich plasma (PRP) composition are provided. Any type of arrhythmia may be treated using the PRP composition. The PRP composition may comprise PRP developed using blood collected from a patient suffering the cardiac arrhythmia. The PRP composition may be buffered to a physiological pH and may include one or more anti-arrhythmic agents, anti-coagulants, or other drugs. The PRP composition may be delivered using a nebulizer, minimally invasively, or surgically.
1. A method for treating a cardiac conduction abnormality, comprising:
identifying a cardiac conduction abnormality in a patient; and
delivering a platelet rich plasma composition to the patient, wherein the platelet rich plasma composition is in an inhalable form.
2. The method of claim 1 , wherein the conduction abnormality is a cardiac arrhythmia.
3. The method of claim 1 , wherein the patient has a negative cardiac enzyme elevation.
4. The method of claim 1 , further comprising monitoring the conduction abnormality after delivering the platelet rich plasma composition.
5. The method of claim 1 , wherein the conduction abnormality is selected from the group consisting of bradycardia, tachycardia, ventricular tachycardia, and ventricular fibrillation.
6. The method of claim 1 , wherein the conduction abnormality is chronic, acute or episodic.
7. The method of claim 1 , wherein determining a cardiac conduction abnormality exists comprises using an electrocardiogram, Holter monitor or a cardiac event monitor.
8. The method of claim 1 , wherein the platelet rich plasma composition is prepared from whole blood of the patient.
9. The method of claim 1 , wherein the platelet rich plasma composition is buffered to a physiological pH, and wherein the physiological pH is between about 7.3 and about 7.5.
10. The method of claim 1 , wherein the inhalable form is an inhalable powder.
11. The method of claim 1 , wherein the treatment further comprises administering an anti-arrhythmic agent selected from the group consisting of a sodium channel blocker, a beta blocker, a potassium channel blocker, and a calcium channel blocker.
12. The method of claim 1 , wherein the inhalable form is delivered with a nebulizer or inhaler.
13. The method of claim 1 , wherein the conduction abnormality is due at least in part to reperfusion therapy.